Gyre Therapeutics (GYRE) Accounts Payables (2010 - 2026)
Gyre Therapeutics (GYRE) reported Accounts Payables of $265000.0 for Q1 2026, up 117.21% year-over-year from $122000.0 in Q1 2025, and up 113.71% quarter-over-quarter from $124000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Accounts Payables (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 17 years of Accounts Payables data on file, last reported at $265000.0 in Q1 2026.
- Accounts Payables for Q1 2026 came in at $265000.0, up 117.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $265000.0 (up 117.21% YoY), and the FY2025 annual result was $124000.0, up 14.81% from the prior year.
- Accounts Payables rose to $265000.0 in Q1 2026 per GYRE's latest filing, from $124000.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $4.7 million in Q1 2022 and troughed at $5000.0 in Q2 2023.
- A 5-year average of $505294.1 and a median of $158000.0 in 2023 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2023 and 2024: Accounts Payables plunged 99.66% in 2023, then surged 5320.0% in 2024.
- A 5-year view of Accounts Payables shows it stood at $122000.0 in 2022, then surged by 190.98% to $355000.0 in 2023, then plunged by 69.58% to $108000.0 in 2024, then gained by 14.81% to $124000.0 in 2025, then surged by 113.71% to $265000.0 in 2026.
- Business Quant data shows GYRE's Accounts Payables at $265000.0 in Q1 2026, $124000.0 in Q4 2025, and $556000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.05 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 83.00 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 8.64 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 489.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 34.55 Mn |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn | 265,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 265,000.00 |
| Dec 31, 2025 | 124,000.00 |
| Sep 30, 2025 | 556,000.00 |
| Jun 30, 2025 | 71,000.00 |
| Mar 31, 2025 | 122,000.00 |
| Dec 31, 2024 | 108,000.00 |
| Sep 30, 2024 | 303,000.00 |
| Jun 30, 2024 | 271,000.00 |
| Mar 31, 2024 | 330,000.00 |
| Dec 31, 2023 | 355,000.00 |
| Sep 30, 2023 | 158,000.00 |
| Jun 30, 2023 | 5,000.00 |
| Mar 31, 2023 | 16,000.00 |
| Dec 31, 2022 | 122,000.00 |
| Sep 30, 2022 | 41,000.00 |
| Jun 30, 2022 | 1.04 Mn |
| Mar 31, 2022 | 4.71 Mn |
| Dec 31, 2021 | 6.42 Mn |
| Sep 30, 2021 | 3.86 Mn |
| Jun 30, 2021 | 1.83 Mn |